Featured Press Releases

Translational Vision Science and Technology Journal Publishes RadiusXR

Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

  • 30 Sep 2024

Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative...

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio Announces FDA Approval of ANKTIVA®,

China approves the Corina Intrauterine Drug-Eluting System as a novel treatment for moderate-to-severe intrauterine adhesions (IUA)

China approves the Corina Intrauterine Drug-Eluting System as a novel treatment for moderate-to-severe intrauterine adhesions (IUA)

IRBM Expands Functional Genomics Platform for Early Drug Discovery

IRBM Expands Functional Genomics Platform for Early Drug Discovery

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

  • Ibex Medical Analytics
  • 27 Aug 2024
The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

  • iXCells Biotechnologies USA, Inc.
  • 12 Jun 2025
Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

  • Nuvation Bio
  • 12 Jun 2025
Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

  • Avanzanite Bioscience B.V.
  • 11 Jun 2025
Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

  • Lubrizol
  • 11 Jun 2025
CollPlant expands its partnership with Stemcell Technologies.

CollPlant expands its partnership with Stemcell Technologies.

  • CollPlant
  • 10 Jun 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
June   2025
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.